SG11202100348SA - Oligonucleotides for modulating rtel1 expression - Google Patents
Oligonucleotides for modulating rtel1 expressionInfo
- Publication number
- SG11202100348SA SG11202100348SA SG11202100348SA SG11202100348SA SG11202100348SA SG 11202100348S A SG11202100348S A SG 11202100348SA SG 11202100348S A SG11202100348S A SG 11202100348SA SG 11202100348S A SG11202100348S A SG 11202100348SA SG 11202100348S A SG11202100348S A SG 11202100348SA
- Authority
- SG
- Singapore
- Prior art keywords
- oligonucleotides
- modulating
- rtel1
- expression
- rtel1 expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18183477 | 2018-07-13 | ||
PCT/EP2019/068639 WO2020011902A1 (en) | 2018-07-13 | 2019-07-11 | Oligonucleotides for modulating rtel1 expression |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202100348SA true SG11202100348SA (en) | 2021-02-25 |
Family
ID=62951968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202100348SA SG11202100348SA (en) | 2018-07-13 | 2019-07-11 | Oligonucleotides for modulating rtel1 expression |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210147850A1 (en) |
EP (1) | EP3821013A1 (en) |
JP (1) | JP2021524277A (en) |
KR (1) | KR20210033004A (en) |
CN (1) | CN112534055A (en) |
AU (1) | AU2019300324A1 (en) |
BR (1) | BR112021000538A2 (en) |
CA (1) | CA3106288A1 (en) |
CL (1) | CL2021000018A1 (en) |
CR (1) | CR20210015A (en) |
IL (1) | IL279929A (en) |
MX (1) | MX2021000404A (en) |
PE (1) | PE20211306A1 (en) |
SG (1) | SG11202100348SA (en) |
TW (1) | TWI791868B (en) |
WO (1) | WO2020011902A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202246500A (en) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | Enhanced oligonucleotides for inhibiting rtel1 expression |
WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69233046T2 (en) | 1991-10-24 | 2004-03-04 | Isis Pharmaceuticals, Inc., Carlsfeld | DERIVATIZED OLIGONUCLEOTIDS WITH IMPROVED CAPACITY |
JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
EP2341057A3 (en) | 1997-09-12 | 2011-11-23 | Exiqon A/S | Oligonucleotide Analogues |
AU758956B2 (en) | 1999-02-12 | 2003-04-03 | Daiichi Sankyo Company, Limited | Novel nucleosides and oligonucleotide analogues |
EP1178999B1 (en) | 1999-05-04 | 2007-03-14 | Santaris Pharma A/S | L-ribo-lna analogues |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
US7393950B2 (en) * | 2002-08-29 | 2008-07-01 | Hong Kong University Of Science & Technology | Antisense oligonucleotides targeted to human CDC45 |
AU2003281969B2 (en) | 2002-11-18 | 2011-01-27 | Roche Innovation Center Copenhagen A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
WO2004083430A2 (en) | 2003-03-21 | 2004-09-30 | Santaris Pharma A/S | SHORT INTERFERING RNA (siRNA) ANALOGUES |
BRPI0411219A (en) | 2003-06-12 | 2006-07-18 | Nucleonics Inc | conserved hbv and hcv sequences useful for gene silencing |
WO2007094818A2 (en) | 2005-08-10 | 2007-08-23 | Merck & Co., Inc. | Novel hiv targets |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
CA2640171C (en) | 2006-01-27 | 2014-10-28 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
AU2007209481B2 (en) | 2006-01-27 | 2012-01-12 | Roche Innovation Center Copenhagen A/S | LNA modified phosphorothiolated oligonucleotides |
EA015563B1 (en) | 2006-03-23 | 2011-08-30 | Сантарис Фарма А/С | Small internally segmented interfering rna |
ES2389737T3 (en) | 2006-05-11 | 2012-10-31 | Isis Pharmaceuticals, Inc. | 5 'modified bicyclic nucleic acid analogs |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
WO2008150729A2 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
US8278283B2 (en) | 2007-07-05 | 2012-10-02 | Isis Pharmaceuticals, Inc. | 6-disubstituted or unsaturated bicyclic nucleic acid analogs |
WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
EP2356129B1 (en) | 2008-09-24 | 2013-04-03 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
JP5855463B2 (en) | 2008-12-18 | 2016-02-09 | ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. | Extended DICER substrate drugs and methods for specific inhibition of gene expression |
US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
WO2011156202A1 (en) | 2010-06-08 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CN103370415B (en) | 2010-10-28 | 2017-05-31 | 本尼特生物制药有限公司 | HBV is treated |
UA118951C2 (en) | 2011-04-21 | 2019-04-10 | Айоніс Фармасьютікалз, Інк. | Modulation of hepatitis b virus (hbv) expression |
JP6165723B2 (en) | 2011-06-30 | 2017-07-19 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Compositions and methods for inhibiting gene expression of hepatitis B virus |
DK2742136T3 (en) | 2011-08-11 | 2017-11-20 | Ionis Pharmaceuticals Inc | GAPMER COMPOUNDS INCLUDING 5 'MODIFIED DEOXYRIBONUCLEOSIDES IN GAP AND APPLICATIONS THEREOF |
DK2751270T3 (en) | 2011-08-29 | 2018-10-29 | Ionis Pharmaceuticals Inc | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE |
US9221864B2 (en) | 2012-04-09 | 2015-12-29 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
EP2920304B1 (en) | 2012-11-15 | 2019-03-06 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
NZ631512A (en) | 2013-05-01 | 2016-10-28 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating apolipoprotein (a) expression |
US20160138114A1 (en) * | 2013-06-19 | 2016-05-19 | The Regents Of The University Of California | Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer |
MY183049A (en) | 2013-06-27 | 2021-02-09 | Roche Innovation Ct Copenhagen As | Antisense oligomers and conjugates targeting pcsk9 |
KR102287532B1 (en) | 2014-01-30 | 2021-08-11 | 에프. 호프만-라 로슈 아게 | Poly oligomer compound with biocleavable conjugates |
GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
US20170327524A1 (en) | 2014-10-10 | 2017-11-16 | Hoffmann-La Roche, Inc. | Galnac phosphoramidites, nucleic acid conjugates thereof and their use |
CA2996722A1 (en) | 2015-07-17 | 2017-01-26 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
CN108271387B (en) | 2015-08-07 | 2023-06-27 | 箭头药业股份有限公司 | RNAi therapy of hepatitis B virus infection |
MA45496A (en) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | NUCLEIC ACID MOLECULES FOR PADD5 OR PAD7 MRNA REDUCTION FOR TREATMENT OF HEPATITIS B INFECTION |
CN117757791A (en) | 2016-11-23 | 2024-03-26 | 阿尔尼拉姆医药品有限公司 | Modified RNA agents with reduced off-target effects |
-
2019
- 2019-07-11 CA CA3106288A patent/CA3106288A1/en active Pending
- 2019-07-11 AU AU2019300324A patent/AU2019300324A1/en not_active Abandoned
- 2019-07-11 PE PE2020002231A patent/PE20211306A1/en unknown
- 2019-07-11 CN CN201980047097.2A patent/CN112534055A/en active Pending
- 2019-07-11 BR BR112021000538-2A patent/BR112021000538A2/en unknown
- 2019-07-11 JP JP2021500833A patent/JP2021524277A/en active Pending
- 2019-07-11 KR KR1020217004297A patent/KR20210033004A/en not_active Application Discontinuation
- 2019-07-11 EP EP19739971.0A patent/EP3821013A1/en active Pending
- 2019-07-11 CR CR20210015A patent/CR20210015A/en unknown
- 2019-07-11 SG SG11202100348SA patent/SG11202100348SA/en unknown
- 2019-07-11 MX MX2021000404A patent/MX2021000404A/en unknown
- 2019-07-11 WO PCT/EP2019/068639 patent/WO2020011902A1/en unknown
- 2019-07-12 TW TW108124604A patent/TWI791868B/en active
-
2021
- 2021-01-03 IL IL279929A patent/IL279929A/en unknown
- 2021-01-05 CL CL2021000018A patent/CL2021000018A1/en unknown
- 2021-01-13 US US17/147,797 patent/US20210147850A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021524277A (en) | 2021-09-13 |
TW202020152A (en) | 2020-06-01 |
PE20211306A1 (en) | 2021-07-20 |
CA3106288A1 (en) | 2020-01-16 |
TWI791868B (en) | 2023-02-11 |
CR20210015A (en) | 2021-03-22 |
EP3821013A1 (en) | 2021-05-19 |
CL2021000018A1 (en) | 2021-07-09 |
MX2021000404A (en) | 2021-03-25 |
AU2019300324A1 (en) | 2021-01-21 |
US20210147850A1 (en) | 2021-05-20 |
BR112021000538A2 (en) | 2021-04-06 |
IL279929A (en) | 2021-03-01 |
KR20210033004A (en) | 2021-03-25 |
WO2020011902A1 (en) | 2020-01-16 |
CN112534055A (en) | 2021-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202007542B (en) | Oligonucleotides for modulating scn9a expression | |
SG11201911704UA (en) | Antisense oligonucleotides for modulating the function of a t cell | |
RS64073B1 (en) | Tmem16a modulators | |
ZA201808291B (en) | Antisense oligonucleotides for modulating htra1 expression | |
IL279056A (en) | Oligonucleotides for modulating tau expression | |
GB2594008B (en) | Modulators | |
IL276357A (en) | Oligonucleotides for modulating tmem106b expression | |
GB201908106D0 (en) | No details | |
IL271039A (en) | Antisense oligonucleotides for modulating htra1 expression | |
IL279929A (en) | Oligonucleotides for modulating rtel1 expression | |
GB201905867D0 (en) | No details | |
IL282731A (en) | Organosulfur compounds | |
EP4041248A4 (en) | Modified oligonucleotides | |
GB2585587B (en) | Modulators | |
EP3819231C0 (en) | Application container | |
GB201714330D0 (en) | Oligonucleotides | |
GB201608907D0 (en) | Means for modulating gene expression | |
GB201918974D0 (en) | Gpr52 modulator compounds | |
GB201918992D0 (en) | GPR52 modulator compounds | |
GB201916298D0 (en) | GPR52 modulator compounds | |
SG11202011746UA (en) | Application container | |
ZA201905705B (en) | Dispensing arrangement | |
GB201904663D0 (en) | No details | |
GB201813574D0 (en) | A1 | |
GB201809799D0 (en) | No Details |